News | September 22, 2010

FDA-Cleared OCT Intravascular Imaging System on Display at TCT

September 22, 2010 - A new intravascular imaging system will be highlighted at the annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. The C7-XR optical coherence tomography (OCT) platform, made by St. Jude Medical, offers physicians a new tool for intravascular lesion assessment.

The system uses near-infrared light to create high-resolution images, allowing physicians to visualize and measure important vessel characteristics that are otherwise invisible or difficult to assess. While fractional flow reserve (FFR) accurately identifies which lesions to stent, OCT-guided treatment can be especially important for assessing stent placement because it shows precisely how the stent is positioned against the artery wall.

In addition to guiding stent selection, the C7-XR System provides physicians with post-stenting information by evaluating the position and deployment of the stent. At follow-up, the technology provides detailed information regarding the inner lining of the vessel and whether there is a reoccurrence of the blood vessel narrowing.

Physicians can learn more about OCT-guided therapy by participating in virtual reality simulations. The simulator enables physicians to manipulate the C7-XR Dragonfly catheter, performing OCT-guided procedures in human-size models and selecting from a variety of case scenarios. The sessions will take place on Sept. 23 and Sept. 24 from 9 a.m. to 5 p.m. and on Sept. 25 from 9 a.m. to 2 p.m. at the St. Jude Medical booth.

St. Jude Medical will also sponsor a scientific symposium entitled, "OCT & FFR, Current Applications, Future Potential." The symposium will take place on Thursday, Sept. 23 from 7 p.m. to 9:30 p.m. in the Renaissance Ballroom, located in the Renaissance Washington, D.C. Downtown Hotel.

For more information:

Related Content

SCAI and the European Society of Cardiology recently added iFR to their guidelines.

An illustration of Philip’s iFR technology, showing the iFR pressure readings and a fusion angio image indicating pressure drops in the vessel during wire pull back. SCAI and the European Society of Cardiology recently added iFR to their guidelines.

Feature | FFR Technologies | September 05, 2018 | Dave Fornell, Editor
The use of invasive, pressure wire-based fractional flow reserve (FFR) in the cath lab is now considered the gold sta
European Society of Cardiology Incorporates iFR Technology Into Updated Revascularization Guidelines
News | FFR Technologies | August 29, 2018
Philips announced that the European Society of Cardiology (ESC) has incorporated instantaneous wave-free ratio (iFR)...
iFR reference numbers posted for new users in the cath lab at Northwestern Medicine's Central DuPage Hospital in Winfield, Ill.
News | FFR Technologies | July 26, 2018
July 26, 2018 — The Society of Cardiac Angiography and Interventions (SCAI) released a focused update expert consensu
CathWorks Receives CPT Code for Non-invasive FFRangio Measurements During PCI
News | FFR Technologies | July 12, 2018
CathWorks announced the approval of a new Current Procedural Terminology (CPT) code 0523T for non-invasive, 3-D...
The ORBITA Trial showed FFR and iFR are good predictors of PCI outcomes. This was a 2018 PCR late-breaker.
News | FFR Technologies | May 29, 2018
May 29, 2018 — The first placebo-controlled trial that looked at how fractional flow reserve (FFR) and instantaneous
FAST Study Demonstrates High Diagnostic Accuracy of CAAS vFFR
Technology | FFR Technologies | May 22, 2018
Pie Medical Imaging announced that clinical data on its CAAS vFFR (Cardiovascular Angiographic Analysis Systems for...
HeartFlow FFRct Analysis Added to ITP Payment Program in the U.K.
News | FFR Technologies | April 25, 2018
HeartFlow Inc. announced that the National Health Service (NHS) England has chosen the HeartFlow FFRct (fractional flow...
Videos | FFR Technologies | March 15, 2018
An economic analysis of the DEFINE-FLAIR study comparing FFR vs. iFR, found a cost savings of nearly $900.
iFR More Cost-Effective Than FFR in PCI Guidance
News | FFR Technologies | March 12, 2018
Philips announced health economic results from the DEFINE FLAIR clinical trial comparing cost-effectiveness between...
BlueCross BlueShield Companies in Eight States Issue Positive Medical Policies for HeartFlow FFRct Analysis
News | FFR Technologies | December 28, 2017
HeartFlow Inc. announced that Health Care Service Corp. (HCSC), which operates Blue Cross and Blue Shield plans in five...
Overlay Init